title: Antibodies against p40tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection.
abstract: We investigated antibodies against pX gene product, p40tax, by ELISA using recombinant p40tax protein in HTLV-I seropositive carriers as well as patients with adult T cell leukemia (ATL) and HTLV-I-associated myelopathy (HAM). Seventy (49.0%) out of 143 HTLV-I healthy carriers were found to be positive for antibody against p40tax antigen and the follow-up samples at two-year intervals revealed constant reactivity by ELISA in each carrier. The onset of antibody production was delayed 4 to 12 weeks as compared with anti-HTLV-I in primary infection cases. The anti-p40tax-positive rate (90%) in HAM patients was significantly higher than that of healthy carriers, acute and chronic ATL patients and their family members. Furthermore, HAM patients and a few healthy carriers showed high reactivities by ELISA. Children from mothers with anti-p40tax showed a higher anti-HTLV-I-positive rate than that of children from mothers without anti-p40tax (54.5% versus 12.5%). Two men without anti-p40tax and one female with low anti-p40tax developed ATL during follow-up studies. These results suggest that HTLV-I carriers could be divided into 2 or 3 sub-populations according to antibody response to p40tax. A smaller population with anti-p40tax, especially a high antibody reactivity, could have a high risk of developing HAM and of transmission from mother to child. In addition, ATL may occur in a population with low or absent anti-p40tax.
authors.affiliation: Blood Transfusion Service, School of Medicine, Nagasaki University.
authors.forename: S
authors.initials: S
authors.lastname: Kamihira
authors.forename: K
authors.initials: K
authors.lastname: Toriya
authors.forename: T
authors.initials: T
authors.lastname: Amagasaki
authors.forename: S
authors.initials: S
authors.lastname: Momita
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Tomonaga
authors.forename: M
authors.initials: M
authors.lastname: Ichimaru
authors.forename: K
authors.initials: K
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Sawada
mesh_terms: D002353:Carrier State; D005260:Female; D005500:Follow-Up Studies; D015481:HTLV-I Antibodies / Q000032:analysis*; D015490:HTLV-I Infections / Q000276:immunology*; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D007231:Infant, Newborn; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology; D012191:Retroviridae Proteins / Q000276:immunology*; D013118:Spinal Cord Diseases / Q000209:etiology; D014764:Viral Proteins / Q000276:immunology*
chemical_list: D015481:HTLV-I Antibodies; D012191:Retroviridae Proteins; D014764:Viral Proteins